市場調查報告書
商品編碼
1447028
2030 年維吉尼亞市場預測:按類型、動物、分銷管道、應用和地區進行的全球分析Virginiamycin Market Forecasts to 2030 - Global Analysis By Type (Poultry, Aquaculture and Other Types), Animal (Companion Animals, Cattle, Swine and Other Animals), Distribution Channel, Application and by Geography |
根據 Stratistics MRC 的數據,2023 年全球維吉尼亞市場規模為 1.8505 億美元,預計預測期內年複合成長率為 7.5%,到 2030 年將達到 3.0701 億美元。
維吉尼亞是一種強效抗生素,也可用作牲畜和家禽的飼料添加劑,以促進生長並防止細菌感染。這種抗生素由兩種密切相關的成分(維吉尼亞M1 和維吉尼亞S1)組成,屬於鏈黴素組。此外,這些元素還可以透過阻止細胞內的蛋白質合成來抑制細菌生長。其對革蘭氏陽性菌的出色功效使維吉尼亞黴素成為疾病預防和促進動物健康的寶貴工具。
根據美國獸醫協會 (AVMA) 的說法,負責任地使用抗生素(包括維吉尼亞等化合物)對於確保農業環境中動物的健康和福祉至關重要。
增加畜牧業產量
全球畜產品需求不斷成長是推動維吉尼亞市場的主要因素之一。隨著世界人口持續成長以滿足對肉類和乳製品日益成長的需求,高效和永續的畜牧生產變得越來越重要。此外,維吉尼亞是有利於集中畜牧業實踐的主要因素,因為它有助於預防感染疾病並促進牲畜生長。
對抗生素抗藥性的擔憂
對抗生素抗藥性的日益擔憂是影響維吉尼亞市場的主要因素之一。在家畜中廣泛且持續地使用維吉尼亞黴素等抗生素可能是導致抗藥性細菌出現的因素。此外,抗藥性細菌可以透過食物鏈傳播給人類,不僅使牲畜而且使公共衛生面臨風險。它還會降低抗生素的長期有效性。
擴大精準畜牧業的使用
在自動化、資料分析和感測器技術進步的推動下,維吉尼亞市場預計將受益於精準畜牧業的日益成長。此外,可以精確應用維吉尼亞和其他飼料添加劑,以最大限度地提高生長和健康結果。精密農業可以更精確地監測動物健康參數和飼料效率。
加強監管約束
加強對畜牧生產中抗生素使用的監管審查和收緊法規對維吉尼亞市場構成了嚴重威脅。對抗生素抗藥性的擔憂導致各國政府和國際組織制定更嚴格的法規,這可能會限制維吉尼亞的供應和使用。此外,市場參與企業還面臨遵守不斷變化的監管標準的挑戰。
由於供應鏈中斷、勞動力短缺和經濟不確定性影響了整個農業和畜牧業,COVID-19 大流行對維吉尼亞市場產生了重大影響。疫情帶來的關閉和限制造成了物流挑戰,阻礙了維吉尼亞等飼料添加劑的生產和分銷。此外,由於經濟衝擊,一些家牛生產者重新考慮了他們的支出,這可能會影響這些添加劑的市場。
預計在預測期內家禽市場將成為最大的市場
家禽養殖佔維吉尼亞市場的最大佔有率。家禽業廣泛使用維吉尼亞作為飼料添加劑,以促進生長並保護雞和其他家禽免受細菌感染。由於人口成長和飲食偏好的變化,世界對家禽產品的持續需求,對有效和永續的家禽養殖的需求正在增加。此外,維持雞群健康和產量的有用工具是維吉尼亞,因為它具有對抗革蘭氏陽性菌的效力。
牛和家禽飼料添加劑領域預計在預測期內年複合成長率最高。
牛和家禽飼料添加劑是年複合成長率最高的維吉尼亞市場。由於對肉類和家禽產品的需求不斷增加以及對永續動物生產方法的需求,該市場正在顯著擴大。維吉尼亞是一種抗生素飼料添加劑,因其治療和預防牛和家禽疾病(如球蟲和壞死性小腸結腸炎)的能力而受到高度重視。此外,它還能刺激生長,提高飼料轉換效率,促進體重增加,並改善動物的整體健康狀況。
北美可能佔據維吉尼亞市場的最大佔有率。北美地區畜牧業發達,對肉禽產品的需求量大,是維吉尼亞的主要消費國。以維吉尼亞作為牛和家禽飼料添加劑也受到該地區嚴格的食品安全和動物健康法規的影響。此外,推廣永續動物生產方法也是北美的重點優先事項,支持該地區維吉尼亞市場的擴張。
預計亞太地區維吉尼亞市場的年複合成長率最高。在亞太地區,作為牛和家禽飼料添加劑的維吉尼亞的需求大幅增加。這一成長的主要驅動力是由於人口成長、可支配收入增加和飲食偏好變化而導致的肉類和家禽產品消費量的增加。此外,該地區正在轉向更加集中的畜牧方式,因此需要使用維吉尼亞等抗生素來預防感染疾病並促進生長。
According to Stratistics MRC, the Global Virginiamycin Market is accounted for $185.05 million in 2023 and is expected to reach $307.01 million by 2030 growing at a CAGR of 7.5% during the forecast period. Virginiamycin is a strong antibiotic that is also used as a feed additive in livestock and poultry farming to boost growth and guard against bacterial infections. Virginiamycin M1 and Virginiamycin S1, its two closely related components, make up this antibiotic that is a member of the streptogramin group. Additionally, these elements suppress bacterial growth by preventing protein synthesis in the cells. Due to its exceptional efficacy against Gram-positive bacteria, Virginiamycin is a valuable tool for disease prevention and enhancing animal health in general.
According to the American Veterinary Medical Association (AVMA), the responsible use of antibiotics, including compounds such as Virginiamycin, is crucial in ensuring the health and well-being of animals in agricultural settings.
Increasing production of livestock
The growing demand for livestock products worldwide is one of the major factors driving the Virginiamycin market. To meet the rising demand for meat and dairy products, efficient and sustainable livestock production is becoming more and more important as the world's population continues to rise. Moreover, virginiamycin is a major factor in favor of intensive animal farming practices because it helps to prevent infections and promote growth in livestock.
Antibiotic resistance concerns
The increasing worry about antibiotic resistance is one of the major factors affecting the Virginiamycin market. The widespread and ongoing use of antibiotics, such as Virginiamycin, in cattle may be a factor in the emergence of bacterial strains that are resistant. Furthermore, due to the fact that resistant bacteria may spread to humans via the food chain, this puts public health at risk in addition to that of animals. It also reduces the antibiotics' long-term efficacy.
Growing use of accurate livestock production
The market for virginiamycin is expected to benefit from the increasing use of precision livestock farming, which is being fueled by developments in automation, data analytics, and sensor technologies. Moreover, virginiamycin and other feed additives can be applied precisely to maximize growth and health outcomes. Precision farming makes it possible to monitor animal health parameters and feed efficiency more precisely.
Growing restraints on regulations
The increasing regulatory scrutiny and tightening restrictions on the use of antibiotics in livestock farming pose a serious threat to the Virginiamycin market. Stricter regulations are being put in place by governments and international organizations in response to worries about antibiotic resistance, which may restrict the supply and use of Virginiamycin. Furthermore, market participants face challenges in adhering to changing regulatory standards.
Due to supply chain disruptions, labor shortages, and economic uncertainties that have impacted the entire agriculture and livestock industry, the COVID-19 pandemic has had a significant impact on the Virginiamycin market. Lockdowns and restrictions brought on by the pandemic created logistical difficulties that hampered the manufacture and distribution of feed additives, such as Virginiamycin. Moreover, some cattle producers have reevaluated their expenditures as a result of the economic fallout, which could affect the market for these additives.
The Poultry segment is expected to be the largest during the forecast period
In the market for Virginiamycin, poultry farming has the largest share. To encourage growth and guard against bacterial infections in hens and other poultry species, the poultry industry uses Virginiamycin as a feed additive liberally. The need for effective and sustainable poultry farming practices has grown as a result of the world's constant demand for poultry products, which is being driven by population growth and shifting food preferences. Additionally, a useful tool for preserving the wellbeing and output of chicken flocks is Virginiamycin, due to its potency against Gram-positive bacteria.
The Feed Additive for Cattle and Poultry segment is expected to have the highest CAGR during the forecast period
Feed Additive for Cattle and Poultry is the Virginiamycin market segment with the highest CAGR. Due to the rising demand for meat and poultry products as well as the necessity of using sustainable animal production methods, this market is expanding significantly. The antibiotic feed additive virginiamycin is highly prized for its ability to treat and prevent diseases in cattle and poultry, including coccidiosis and necrotic enteritis. Furthermore, it also stimulates growth, increasing feed conversion effectiveness, encouraging weight gain, and improving the general health of the animal.
North America is probably the region with the largest share of the Virginiamycin market. Because of its well-established livestock industry and strong demand for meat and poultry products, North America is a major consumer of Virginiamycin. The adoption of Virginiamycin as a feed additive for cattle and poultry is also influenced by the region's strict regulations regarding food safety and animal health. Moreover, the promotion of sustainable animal production methods is another major priority in North America, which supports the expansion of the Virginiamycin market there.
The Asia-Pacific region is anticipated to have the highest CAGR in the Virginiamycin market. The demand for Virginiamycin as a feed additive for cattle and poultry is rising significantly in the Asia-Pacific area. The growing population, rising disposable income, and shifting dietary preferences-which result in a greater consumption of meat and poultry products-are the main drivers of this growth. Furthermore, the area is witnessing a transition towards more intensive methods of animal husbandry, thereby requiring the application of antibiotics such as Virginiamycin to prevent infections and enhance growth.
Key players in the market
Some of the key players in Virginiamycin market include Elanco, Merck Animal Health, Ceva, Merial, Bayer Animal Health, Phibro Animal Health Corporation, Vetoquinol, Boehringer Ingelheim, Virbac and Zoetis.
In November 2023, CEVA Logistics completed its acquisition of Stellar Value Chain. CEVA acquired a 96% stake in the Mumbai-based warehousing and transportation specialists from an affiliate of private equity form Warburg Pincus and other shareholders. The acquisition adds to CEVA's existing presence in India, allowing for the delivery of holistic supply chain services to customers across the Asia Pacific region and beyond.
In August 2023, Merck Animal Health announced Dec. 6 that it has acquired Prondil S.A., a privately held company specializing in the development and manufacturing of animal health vaccines for livestock. Specific terms of the agreement were not disclosed. Prondil, located in Montevideo, Uruguay, is an internationally recognized supplier of antigens and vaccines for veterinary use. The company's wide range of products is sold in more than 20 countries.
In May 2023, Elanco Animal Health Incorporated has entered into an agreement with Aptimmune Biologics, Inc., as the exclusive distributor of their porcine reproductive and respiratory syndrome inactivated, or killed, vaccine based on Aptimmune's Barricade technology platform in the United States. An inactivated vaccine is one consisting of virus particles, bacteria or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity.